SI1536783T1 - Trdne formulacije, ki vsebujejo indolinonsko spojino - Google Patents

Trdne formulacije, ki vsebujejo indolinonsko spojino

Info

Publication number
SI1536783T1
SI1536783T1 SI200331328T SI200331328T SI1536783T1 SI 1536783 T1 SI1536783 T1 SI 1536783T1 SI 200331328 T SI200331328 T SI 200331328T SI 200331328 T SI200331328 T SI 200331328T SI 1536783 T1 SI1536783 T1 SI 1536783T1
Authority
SI
Slovenia
Prior art keywords
solid formulations
indolinone compound
indolinone
compound
formulations
Prior art date
Application number
SI200331328T
Other languages
English (en)
Inventor
Paolo Gatti
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1536783(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Publication of SI1536783T1 publication Critical patent/SI1536783T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200331328T 2002-09-10 2003-09-10 Trdne formulacije, ki vsebujejo indolinonsko spojino SI1536783T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10
EP03772489A EP1536783B2 (en) 2002-09-10 2003-09-10 Solid formulations comprising an indolinone compound
PCT/IB2003/005293 WO2004024127A2 (en) 2002-09-10 2003-09-10 Solid formulations comprising an indolinone compound

Publications (1)

Publication Number Publication Date
SI1536783T1 true SI1536783T1 (sl) 2008-12-31

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331328T SI1536783T1 (sl) 2002-09-10 2003-09-10 Trdne formulacije, ki vsebujejo indolinonsko spojino

Country Status (31)

Country Link
US (1) US20040229930A1 (sl)
EP (1) EP1536783B2 (sl)
JP (1) JP2006503032A (sl)
KR (1) KR20050059170A (sl)
CN (1) CN1688304A (sl)
AR (1) AR041193A1 (sl)
AT (1) ATE403425T1 (sl)
AU (1) AU2003280108B2 (sl)
BR (1) BR0314182A (sl)
CA (1) CA2498415C (sl)
DE (1) DE60322720D1 (sl)
DK (1) DK1536783T3 (sl)
DO (1) DOP2003000708A (sl)
ES (1) ES2309363T5 (sl)
GT (1) GT200300193A (sl)
HN (1) HN2003000272A (sl)
MX (1) MXPA05002690A (sl)
MY (1) MY136767A (sl)
NL (1) NL1024261C (sl)
NO (1) NO20051670L (sl)
NZ (1) NZ538636A (sl)
PA (1) PA8581801A1 (sl)
PE (1) PE20040989A1 (sl)
PL (1) PL375978A1 (sl)
PT (1) PT1536783E (sl)
RU (1) RU2005110663A (sl)
SI (1) SI1536783T1 (sl)
TW (1) TW200418836A (sl)
UY (1) UY27969A1 (sl)
WO (1) WO2004024127A2 (sl)
ZA (1) ZA200501897B (sl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003661A (es) 2003-10-02 2006-06-05 Pharmacia & Upjohn Co Llc Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
EP1928462A1 (en) * 2005-09-20 2008-06-11 Pfizer Products Incorporated Dosage forms and methods of treatment using a tyrosine kinase inhibitor
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CA2699306A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009100929A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8618309B2 (en) 2008-07-24 2013-12-31 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CA2704448A1 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
ES2715890T3 (es) 2013-11-01 2019-06-06 Pfizer Vectores de expresión de antígenos asociados a la próstata
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
KR20210113290A (ko) 2019-01-09 2021-09-15 셀진 코포레이션 (s)-4-(4-(4-(((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조나이트릴을 포함하는 약제학적 조성물 및 이의 사용 방법
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
DE122010000004I1 (de) * 2000-02-15 2010-04-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
ZA200501897B (en) 2005-09-07
AR041193A1 (es) 2005-05-04
CA2498415C (en) 2007-05-29
AU2003280108B2 (en) 2007-04-05
NL1024261C (nl) 2010-04-06
CN1688304A (zh) 2005-10-26
DOP2003000708A (es) 2004-03-31
DK1536783T3 (da) 2008-10-13
EP1536783B1 (en) 2008-08-06
WO2004024127A3 (en) 2004-06-03
KR20050059170A (ko) 2005-06-17
NO20051670L (no) 2005-04-04
AU2003280108A1 (en) 2004-04-30
ES2309363T3 (es) 2008-12-16
UY27969A1 (es) 2004-04-30
GT200300193A (es) 2004-04-29
TW200418836A (en) 2004-10-01
JP2006503032A (ja) 2006-01-26
WO2004024127A2 (en) 2004-03-25
ATE403425T1 (de) 2008-08-15
NL1024261A1 (nl) 2004-03-11
DE60322720D1 (de) 2008-09-18
US20040229930A1 (en) 2004-11-18
PL375978A1 (en) 2005-12-12
MY136767A (en) 2008-11-28
HN2003000272A (es) 2008-07-29
ES2309363T5 (es) 2011-12-07
NZ538636A (en) 2006-04-28
EP1536783A2 (en) 2005-06-08
PA8581801A1 (es) 2005-02-04
EP1536783B2 (en) 2011-08-24
MXPA05002690A (es) 2005-05-05
PT1536783E (pt) 2008-10-10
BR0314182A (pt) 2005-08-09
RU2005110663A (ru) 2005-09-10
PE20040989A1 (es) 2004-12-28
CA2498415A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
SI1536783T1 (sl) Trdne formulacije, ki vsebujejo indolinonsko spojino
IL162642A0 (en) Formulations
TW507630U (en) Improved structure for socket
IL165349A0 (en) Microcapsule formulations
IL166424A0 (en) Sustained release formulations comprising lamotigine
HK1080385A1 (en) Solid preparation
EP1689389A4 (en) Indole compounds
GB0323701D0 (en) Formulations
PL397821A1 (pl) Związek1-acetylo-6-fluoro-2-indolinon
GB0204241D0 (en) Compound
AU2002951396A0 (en) Horseshoe
GB0218194D0 (en) Solid formulations
ZA200409971B (en) Powder formulations.
GB0307765D0 (en) Tissue-adhesive formulations
PL364014A1 (en) Veterinary compounds
GB0224830D0 (en) Compound
GB0226076D0 (en) Improved formulations containing substituted imidazole derivatives
GB0204392D0 (en) Pharmaceutical compound
GB0214147D0 (en) Formulations
GB0213027D0 (en) Compound
AU2003231306A8 (en) Carvedilol formulations
GB0305560D0 (en) Fuel formulations
AU2003216382A8 (en) Idothyronine compositions
GB0218567D0 (en) Formulations
AU2002952094A0 (en) Bioherbicidal formulations